Drug Profile
Research programme: ophthalmic therapies - Bayer HealthCare/Johns Hopkins University
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Bayer HealthCare; Johns Hopkins University
- Class Eye disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Retinal-disorders in Germany (Ophthalmic)
- 28 Jul 2019 No recent reports of development identified for research development in Retinal-disorders in USA (Ophthalmic)
- 16 Jun 2015 Early research in Retinal disorders in USA and Germany (Ophthalmic)